ライフサイエンスコーパス: drug delivery system

1 gs are a promising multifunctional antitumor drug delivery system.

2 ing a salient feature of this tumor-targeted drug delivery system.

3 a new nanoformulation for use as an anti-TB drug delivery system.

4 1B transporters is affected by the choice of drug delivery system.

5 ovel approach for cell-based therapeutic and drug delivery system.

6 general, emphasized and investigated in each drug delivery system.

7 ere determined by the characteristics of the drug delivery system.

8 le physicochemical properties for a targeted drug delivery system.

9 hanol fluorescent organic nanoparticles as a drug delivery system.

10 Implantation of an intravitreal FA sustained drug delivery system.

11 is controlled with the use of an implantable drug delivery system.

12 onstrate the promise of a gel depot as an IP drug delivery system.

13 agement of lung cancer requires an efficient drug delivery system.

14 vide a platform to develop novel anti-cancer drug delivery system.

15 aneous injection in a microparticle/hydrogel drug-delivery system.

16 lymer science that enables precise design of drug delivery systems.

17 e promising to develop diagnostic probes and drug delivery systems.

18 on of clinically-relevant controlled release drug delivery systems.

19 ved accelerated in vivo release of polymeric drug delivery systems.

20 possible applications in drug synthesis and drug delivery systems.

21 g bioavailability is a key consideration for drug delivery systems.

22 l research and development led to commercial drug delivery systems.

23 iew the mechanisms by which UV light affects drug delivery systems.

24 use for remote control of nanomedicines and drug delivery systems.

25 nce of the clinical and commercial impact of drug delivery systems.

26 rtant tools for developing clinically useful drug delivery systems.

27 ssible when combined with molecular-targeted drug delivery systems.

28 d be modified to home to and refill hydrogel drug delivery systems.

29 ereof as potential building blocks for novel drug delivery systems.

30 velop successful and cost-effective EV-based drug delivery systems.

31 tools allow new ways to manufacture and test drug delivery systems.

32 c applications of cellular hitchhiking-based drug delivery systems.

33 gical processes and developing intracellular drug delivery systems.

34 hat can be exploited for stimulus-responsive drug delivery systems.

35 of CNTs with polymers to produce anticancer drug delivery systems.

36 tential as carriers for therapeutics in oral drug delivery systems.

37 nsiderably widen the gap of possibilities in drug delivery systems.

38 ind applications in cellular NIR imaging and drug delivery systems.

39 elease kinetics from biodegradable polymeric drug delivery systems.

40 de a crucial tool for the rational design of drug delivery systems.

41 pheroids as an in vitro platform for testing drug delivery systems.

42 te form, and the integrity of enteric-coated drug delivery systems.

43 sion, and treatment, including evaluation of drug delivery systems.

44 a wide assortment of tissue engineering and drug delivery systems.

45 ance systems, catheters, ablative tools, and drug delivery systems.

46 of the strengths and limitations of current drug delivery systems.

47 are essential for the design of extraocular drug delivery systems.

48 e design of the next-generation of nanoscale drug delivery systems.

49 echnology, nanomedicine, and many nano-sized drug delivery systems.

50 problem, researchers are investigating novel drug delivery systems.

51 ducts, ranging from processed foods to novel drug delivery systems.

52 ing cellular uptake and nuclear targeting of drug delivery systems.

53 g MDR and recent progress of combined NO and drug delivery systems.

54 applicability of dSTORM for use in studying drug delivery systems.

55 py, oral drug delivery systems, and biologic drug delivery systems.

56 m demonstrated herein are key for successful drug delivery systems.

57 explored for endocytosis and transcytosis of drug delivery systems.

58 ising potential for developing the efficient drug delivery systems.

59 orward toward the development of implantable drug-delivery systems.

60 new alternative for the design of nanosized drug-delivery systems.

61 pplication in microfluidics and miniaturized drug-delivery systems.

62 iomolecules is crucial for improving current drug-delivery systems.

63 st chemistry of pharmaceuticals in nanosized drug-delivery systems.

64 e report the disease-driven engineering of a drug delivery system, a 'nanocell', which overcomes thes

65 cterization of solid microparticles as nasal drug delivery systems able to increase the nose-to-brain

66 mprehensively describes various NPs-mediated drug delivery systems according to different NPs species

67 Use of advanced drug delivery systems (ADDSs) may help to circumvent the

68 strated the antibacterial capability of this drug delivery system against Escherichia coli by the dis

69 Balloon-based drug delivery systems allow localized application of dru

70 The drug delivery system also comprises a semi-automatic rec

71 context, we review recent development of PTX drug delivery systems and analyze the design principles

72 bacteria-enabled systems including biohybrid drug delivery systems and biohybrid mobile sensor networ

73 other applications, such as optoelectronics, drug delivery systems and even lithium-ion batteries.

74 rates the development of magnetically guided drug delivery systems and its potential on efficient ant

75 ge the beneficial features of both polymeric drug delivery systems and liposomes in a single nanocarr

76 Yet, despite potential as drug delivery systems and radiotracers, such filled-and-

77 new biomaterials for tissue engineering, as drug delivery systems and so on.

78 y, drug delivery for localized therapy, oral drug delivery systems, and biologic drug delivery system

79 probes, prototypes of smart therapeutics and drug delivery systems, and explore the future challenges

80 pment of lung-specific particulate vaccines, drug delivery systems, and immunomodulators.

81 Drug delivery systems, and in particular liposomes, have

82 d delivery of bioactive moieties, anticancer drug delivery systems, and theranostics (i.e., real-time

83 Since the design elements of this drug delivery system are already in clinical use (PEG-li

84 jority of clinically used nanoparticle-based drug delivery systems are based on the EPR effect, and,

85 Implanted drug delivery systems are being increasingly used to rea

86 ation and accumulation of nanoparticle-based drug delivery systems are highly dependent on the partic

87 New drug delivery systems are highly needed in research and

88 On-demand drug delivery systems are highly promising to control th

89 Currently available ophthalmic drug delivery systems are inefficient and may lead to si

90 oparticulate drug carriers such as liposomal drug delivery systems are of considerable interest in ca

91 Tumor-targeted drug delivery systems are promising for their advantages

92 Drug delivery systems are required for drug targeting to

93 Development and validation of exosome-based drug delivery systems are the focus of this review.

94 Drug delivery systems are widely researched and develope

95 e the effectiveness of 1.2-mg SMV as a local drug delivery system as an adjunct to scaling and root p

96 introduce these interactions to the micellar drug delivery systems, as well as the effects of these i

97 g method for preclinical assessment of novel drug delivery systems at therapeutic doses in models of

98 nalized mesoporous silica nanoparticle-based drug delivery system (BA-MSN) for glucose-responsive con

99 Herein we developed a nanoparticle drug delivery system based on the assembly of surface-mo

100 one-pot process led to be the most favorable drug delivery system based on the release kinetics point

101 The development of drug delivery systems based on well-defined polymer nano

102 A "relay drug delivery" system based on two distinct modules, whi

103 icular relevance to the field of particulate drug delivery systems, because the low density nature of

104 extensively explored as a means to increase drug delivery systems' biocompatibility and biodegradati

105 biomaterial in many applications, including drug-delivery systems, bone-graft fillers and medical de

106 f the nanosponges not only as a dual release drug delivery system but also enabling a regulated metab

107 and can overcome many drawbacks of existing drug delivery systems by virtue of tunable compositions,

108 d a thermally sensitive gatekeeper, a unique drug delivery system can be produced.

109 understood so that the future development of drug delivery systems can be accelerated and prolific ag

110 ring the pH differences in the body, various drug delivery systems can be designed by utilizing smart

111 The implantable drug-delivery system can be powered with a TENG device r

112 Our results demonstrate that NP drug-delivery systems can promote the readoption of aban

113 is required to optimize and design liposomal drug delivery systems capable of controllable release ta

114 es include skeletal tissues and biominerals, drug delivery systems, catalysts, sensors, separation me

115 of probucol (PB) by constructing a combined drug delivery system (CDDS) composed of nanostructured l

116 face and are highly intriguing for potential drug delivery systems, coating applications, and so fort

117 No synthetic drug delivery system composed of biodegradable polymers

118 The present study reports a drug delivery system comprising nanostructured lipid car

119 A bioinspired cocoon-like anticancer drug delivery system consisting of a deoxyribonuclease (

120 The composite drug delivery system consists of highly-textured superhy

121 Light-controlled drug delivery systems constitute an appealing means to d

122 ortant immune functions, and accumulation of drug delivery systems could have significant implication

123 increasing industrial interest in silk-based drug delivery systems currently at various stages of the

124 ting molecules other than VEGF and using new drug-delivery systems currently are being developed and

125 carbon nanotube (SWNT)-based tumor-targeted drug delivery system (DDS) has been developed, which con

126 Further, we constructed photoresponsive dual drug delivery system (DDS) to release two different anti

127 hemotherapy on healthy organs, we proposed a drug delivery system (DDS) with specific targeting ligan

128 Advanced drug delivery systems (DDS) enhance treatment efficacy o

129 non-toxic liposomes as mitochondria-targeted drug delivery systems (DDS).

130 their importance as site-specific controlled drug delivery systems (DDSs) and has encouraged their ra

131 Major challenges in the development of drug delivery systems (DDSs) have been the short half-li

132 Among drug delivery systems (DDSs), smart nanocarriers that re

133 norganic nanocarriers have been explored for drug delivery systems (DDSs).

134 Systemically injected drug delivery systems distribute into various organs and

135 We previously reported a novel drug delivery system, drug-linker-Phe-Phe-Arg-methylketo

136 Thus, we propose a new drug delivery system, drug-linker-Phe-Phe-Arg-mk-fVIIa,

137 n important role in the fabrication of novel drug delivery systems due to the selective, controlled,

138 gents, delivered concurrently by a nanoscale drug delivery system, e.g. PEG-b-PCL micelles.

139 Several local drug delivery systems employed as monotherapies improved

140 Triggerable drug delivery systems enable on-demand controlled releas

141 e adjunctive use of 0.5% CLM as a controlled drug delivery system enhanced the clinical outcome.

142 e adjunctive use of 0.5% AZM as a controlled drug delivery system enhances the clinical outcome.

143 This physiological drug delivery system facilitates communication between p

144 rmacological efficacy of a female controlled drug delivery system (FcDDS) intended for prevention of

145 sful design of a nanoparticle-based targeted drug delivery system for future clinical translation.

146 e preocular surface and thus are a promising drug delivery system for ophthalmic applications.

147 rrier systems can be a suitable transscleral drug delivery system for poorly water soluble drugs by e

148 Further, an implant-based local drug delivery system for the antibiotic ciprofloxacin wa

149 We present a drug delivery system for the GI tract based on coating s

150 he first intra-articular microparticle-based drug delivery system for the TMJ.

151 To develop a biodegradable polymeric drug delivery system for the treatment of ovarian cancer

152 the desired characteristics of an effective drug delivery system for the treatment of pulmonary dise

153 Is) have shown promise as a sustained, local drug delivery system for therapeutics in a variety of ap

154 on process has been studied to develop smart drug delivery systems for decades.

155 id based nanocarriers can serve as bioactive drug delivery systems for effective treatment of lysosom

156 focus on in vivo validation of such magnetic drug delivery systems for first time, we selected cispla

157 he application of dendritic glycopolymers in drug delivery systems for gene transfection but also as

158 udies and important clinical trials of novel drug delivery systems for glaucoma and evaluates the pot

159 elecoxib microparticles are useful sustained drug delivery systems for inhibiting diabetes-induced el

160 loads for antibody-drug conjugates and other drug delivery systems for personalized targeted cancer c

161 g this non-covalent interaction in nanoscale drug delivery systems for pharmaceutical agents, includi

162 plication of MEs as extravascular injectable drug delivery systems for sustained release.

163 delivery, and tissue engineering.The use of drug delivery systems for the gastrointestinal tract has

164 rticles as formulation components of topical drug delivery systems for the skin has been widely inves

165 The development of drug delivery systems for the targeted and on-demand rel

166 he development of pharmacological agents and drug delivery systems for the treatment of ocular condit

167 Advances in the development of drug delivery systems for these agents are expected to f

168 pecifically nanoparticles and nanofibers, as drug delivery systems for topical and transdermal applic

169 We report here a novel nano-assembled drug-delivery system, formed by multivalent host-guest i

170 In summary, this biodegradable drug delivery system has a great potential to improve pe

171 ns to be seen whether an autocatalytic-based drug delivery system has an advantage to those with non-

172 No periadventitial drug delivery system has reached clinical application.

173 This important modification to our drug delivery system has the ability to deliver therapy

174 in poly(D,L-lactic-co-glycolic acid) (PLGA) drug delivery systems has been identified to play a key

175 potential for use of polymers in controlled drug delivery systems has been long recognized.

176 s and synthetic nanoparticles, many advanced drug delivery systems have been developed that adopt the

177 Nanoparticle-based drug delivery systems have been developed to improve the

178 Drug delivery systems have been developed which can prov

179 Stimuli-triggered drug delivery systems have been increasingly used to pro

180 Numerous local drug delivery systems have been studied to overcome the

181 For more than 60years drug delivery systems have produced numerous controlled

182 rtheless, so far imaging-guided photothermal drug-delivery systems have been developed with limited s

183 properties of these novel nanoconstructs as drug-delivery systems highlight the potential of this ap

184 e increasingly attracted to exploit those as drug delivery systems, highly efficient photothermal mod

185 Clinical outcomes from nano-sized drug delivery systems, however, have indicated that EPR

186 Implantable intrathecal drug delivery systems (IDDS) are basic tool enabling chr

187 he development of implantable and insertable drug delivery systems (IDDS) from their early stage in t

188 xplore the efficacy of 1% ALN gel as a local drug delivery system in adjunct to scaling and root plan

189 cacy of 0.5%, 1%, and 1.5% MF gel as a local drug delivery system in adjunct to scaling and root plan

190 ALN gel compared to a placebo gel as a local drug delivery system in adjunct to scaling and root plan

191 xplore the efficacy of 1% ALN gel as a local drug delivery system in adjunct to scaling and root plan

192 icacy of 1% alendronate (ALN) gel as a local drug delivery system in adjunct to scaling and root plan

193 be used as a novel and effective target for drug delivery system in tumor cells using chemically mod

194 strategy for engineering stimuli-responsive drug delivery systems in a bioinspired and synergistic f

195 Nanoparticles are emerging as targeted drug delivery systems in chronic inflammatory disorders.

196 ategies to overcome these challenges include drug delivery systems in conjunction with other chemical

197 In addition, the loaded drug delivery systems in fibrin scaffolds decreased CSPG

198 Particulate drug delivery systems in general appear to be poised for

199 tistage vector approach over single particle drug delivery systems in mouse models of ovarian and bre

200 roach can be used to monitor accumulation of drug delivery systems in preclinical and clinical studie

201 therapy to [60]fullerene nanoparticle-based drug delivery systems in targeting the micro-vasculature

202 methods used to design and evaluate targeted drug delivery systems in vivo.

203 crucial parameter for their potential use as drug delivery systems in vivo.

204 lenges to clinical translation of nano-based drug delivery systems including in vivo characterization

205 ped a two-component, two-step, pre-targeting drug delivery system integrated with image guidance to c

206 Novel drug delivery systems involving nonbiodegradable or biod

207 This novel drug delivery system is comprised of a thermoresponsive

208 Developing an advanced nucleic acid drug delivery system is of great significance in order t

209 ion mass spectrometry for depth profiling of drug delivery systems is explored.

210 ding blocks in the development of nano-sized drug delivery systems is rapidly growing.

211 The proposed nanoparticulate drug-delivery system is designed for the oral administra

212 erator (TENG)-based self-powered implantable drug-delivery system is presented.

213 to the state of the art, if used as an oral drug delivery system, is the ability to monitor the forc

214 f zero-order release systems, self-regulated drug delivery systems, long-term depot formulations, and

215 Bioabsorbable polymer-coated drug-delivery systems may reduce the risk of late advers

216 Optimal design of epicardial drug delivery systems must consider the underlying bulk

217 Nanotechnology-based drug delivery systems (nanoDDSs) have seen recent popula

218 In particular, nanoparticle-based drug delivery systems not only facilitate the delivery o

219 Effective targeted drug delivery systems often rely on external stimuli to

220 as been utilized in developing polymer-based drug delivery systems over the past 10years.

221 Fibrin scaffolds embedded with the drug delivery systems (PLGA microspheres and lipid micro

222 rface chemistry of polymeric nanoparticulate drug delivery systems (PNDDS) on their adsorption dynami

223 cent reporters being released from polymeric drug delivery systems possess distinct excited-state lif

224 e to produce biofunctional nanovesicle-based drug delivery systems potentially applied to treat vario

225 silica nanosphere (MSN)-based intracellular drug delivery system (PR-AuNPs-MSN) for the photoinduced

226 ne in cancer is the development of effective drug delivery systems, primarily nanoparticles.

227 logies, including actuators, motion sensors, drug delivery systems, projection displays, etc.

228 Nanoparticle-based drug delivery systems provide a highly promising approac

229 The FA drug delivery system provided sustained visual acuity an

230 This novel LGFU-responsive drug delivery system provides a simple and remote approa

231 generation genetically-engineered cell-based drug delivery system, referred to as apoptotic-induced d

232 Sustained release drug delivery systems remain a major clinical need for s

233 tly, MCTS have also been widely exploited in drug delivery system research for comprehensive study of

234 ated to their applications in tumor-targeted drug delivery system research.

235 he potential application of self-emulsifying drug delivery system (SEDDS), that enhances oral absorpt

236 evelopment of plant virus-based materials as drug delivery systems; specifically, this work focuses o

237 hopaedic implants, macroscale and microscale drug delivery systems such as microparticles and wafers

238 Drug delivery systems, such as sub-micrometer polymer ca

239 have been underway to develop more effective drug delivery systems, such as sustained-release drug im

240 A drug delivery system suitable for systemic administratio

241 We hypothesize that a three-drug nanoscale drug delivery system, tailored for lymphatic uptake, adm

242 have the potential to be used as anti-cancer drug delivery systems targeted for the lungs.

243 nexploited potential for use in prodrugs and drug delivery systems targeted to the colon.

244 DK inhibitor conjugates with folic acid as a drug-delivery system targeting folate receptors.

245 IF-1alpha activity we designed a transdermal drug delivery system (TDDS) containing the FDA-approved

246 in-adhesive (DIA) type estradiol transdermal drug delivery systems (TDDS).

247 In conclusion, we developed a biodegradable drug delivery system that accelerated healing processes

248 In conclusion, we have developed a modular drug delivery system that can be targeted to cell types

249 Nanoparticles are a versatile drug delivery system that can overcome physiologic barri

250 in, we report on an effective brain-targeted drug delivery system that combines a robust red blood ce

251 fine-tuning the PK parameters of a targeted drug delivery system that exploits the benefits of both

252 this manuscript, we present a novel micellar drug delivery system that is not only capable of releasi

253 ilability of a systemically active polymeric drug delivery system that passes through the BTB, target

254 with drug-eluting beads (DEB-TACE), a novel drug delivery system that produces a slow and sustained

255 We report a novel nanoparticulate drug delivery system that undergoes reversible volume ch

256 sought-after as a component of intracellular drug delivery systems that could actively propel endosom

257 ed to their development as actively targeted drug delivery systems that expand on and improve current

258 will highlight some of the examples of novel drug delivery systems that have undergone such translati

259 Here we present a targeted, non-invasive drug delivery system to decrease inflammation in an oste

260 porating NLC can be exploited as a promising drug delivery system to improve oral bioavailability and

261 ort the development of an optimized targeted drug delivery system to inhibit advanced stage pancreati

262 stration of the GIRLRG-targeted nanoparticle drug delivery system to irradiated tumors delayed the in

263 her development of a sustainable intraocular drug delivery system to protect RGCs, which may be appli

264 atical models may thus allow optimization of drug delivery systems to achieve a better therapeutic in

265 ies that may be incorporated into these oral drug delivery systems to further enhance drug uptake.

266 the importance in translating liposome-based drug delivery systems to other molecules and cargo.

267 iomedical applications ranging from advanced drug delivery systems to tissue engineering.

268 tes are promising candidates for long-acting drug delivery systems to treat chronic diseases.

269 dy, we demonstrate that a novel transvaginal drug delivery system (TVDS) is capable of delivering pep

270 hylene vinyl acetate (EVA) ring transvaginal drug delivery system (TVDS).

271 Perivascular drug delivery systems typically release drugs to both th

272 s as candidates in applications ranging from drug delivery systems, up to artificial organelles, or a

273 developed a controlled-release nanoparticle drug delivery system using a targeting peptide that reco

274 We have recently developed a novel inner ear drug delivery system using chitosan glycerophosphate (CG

275 interaction, we created a nanovesicle-based drug delivery system using nitrogen cavitation which rap

276 e aim to develop an RGC-targeted intraocular drug delivery system using unimolecular micelle nanopart

277 Targeted drug delivery systems using nanoparticle nanocarriers of

278 drugs, (iii) transdermal systems, (iv) oral drug delivery systems, (v) pulmonary drug delivery, (vi)

279 lasting, slow-release, crystalline antiviral drug delivery system was initially reported using gancic

280 tabilized aggregated nanogel particle (SANP) drug delivery system was prepared for injectable passive

281 The magnetically guided drug delivery system was successfully developed by utili

282 This multicomponent drug delivery system was tested on multidrug-sensitive a

283 Development of new controlled drug delivery systems was very productive during the per

284 As a proof-of-principle of its utility as a drug delivery system, we used the resulting vertex-diffe

285 The resulting drug delivery systems were degraded under acidic conditi

286 y higher in mice receiving the targeted nano-drug delivery system when compared to non-targeted syste

287 osanase as a "switch off" mechanism for this drug delivery system when side effects and potential oto

288 of a minocycline HCl microsphere (MM) local drug-delivery system when used as an adjunct to scaling

289 toxins may be increased by utilization of a drug delivery system which provides selective release of

290 The development of anticancer drug delivery systems which retain or enhance the cytoto

291 onstrate that [S]-PM is a promising targeted drug delivery system, which can be advanced for the trea

292 release system provides a more sophisticated drug delivery system, which can differentiate ATP levels

293 pplicability of a novel nanotechnology-based drug delivery system, which induces recovery of diaphrag

294 hance the biological outcome of nanoparticle drug delivery systems, which often suffer from poor circ

295 us, the concept of a biodegradable polymeric drug-delivery system, which can significantly improve th

296 oth synthetic nanocarriers and cell-mediated drug delivery systems while avoiding their limitations.

297 s to be a noninvasive, externally controlled drug delivery system with cancer-killing properties.

298 Creating nanotechnology-based drug delivery systems with antibacterial and immunomodul

299 rapy can be achieved by designing a targeted drug-delivery system with high stability during circulat

300 f GIRLRG to a sustained-release nanoparticle drug delivery system yielded increased paclitaxel concen